Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.

Abstract: The invention relates to a method for inhibiting pancreatic lipase, or the prophylaxis or treatment of obesity or diabetes mellitus of type 1 and 2, in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones of formula 1: 1

Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydrobenzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.

Abstract: A method for analyzing a liquid test sample by electrochemiluminescence. The method includes at least one specific biochemical binding reaction that leads to the formation of a complex which contains a chemiluminescence marker and the binding of the complex to a magnetic microparticle. Detection is carried out in a measuring cell having a working electrode in order to determine the concentration of the marked microparticle. The detection cycle includes a purification step, a conditioning step, a recovery step and a measuring step. A specified potential profile is applied to the working electrode during these steps. Between the conditioning step and the recovery step, an additional potential pulse with an oxidizing and/or a reducing potential is inserted into the voltage shape of the detection cycle in order to improve the deposit of the microparticle.

Abstract: The present invention relates to a compound named Percyquinnin that is obtainable by cultivating a basidiomycetes Stereum complicatum (DSM 13303), and to its pharmaceutically acceptable salts. The present invention further relates to a process for the production of Percyquinnin and to the use of Percyquinnin and its pharmaceutically acceptable salts as pharmaceuticals, in particular to their use as inhibitors of lipase.

Abstract: Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of the formula 1 in any optically isomeric form, and their physiologically acceptable salts, where R1 is C1-C6-alkyl, C3-C9-cycloalkyl, both of which may be unsubstituted or substituted, and R2 and R3 independently of one another are hydrogen, C6-C10-aryl, C3-C8-cycloalkyl, C6-C10-aryloxymethyl, O-benzyl, O—C6-C10-aryl, O—C3-C8-cycloalkyl, O—C1-C6-alkyl, SO2—NH—C1-C6-alkyl, SO2—NH-(2,2,6,6-tetramethylpiperidin-4-yl), SO2—NH—C3-C8-cycloalkyl, SO2—N(C1-C6-alkyl)2 or COX, where X is O—C1-C6-alkyl, NH—C1-C6-alkyl, NH—C3-C8-cycloalkyl or N(C1-C6-alkyl)2, with the proviso that the substitutents R2 and R3 may in some instances be unsubstituted or substituted and are not both simultaneously hydrogen. A process for their preparation, and their inhibitory effect on the hormone-sensitive lipase, HSL.

Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.

Abstract: The invention relates to pharmaceutical agents containing leptin antagonists for treating Type II diabetes. One leptin antagonist is based on a murine leptin fragment and comprises amino acids 116 to 167 or 116 to 166. Methods of treating Type II diabetes are also disclosed.

Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo [c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.

Abstract: Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of the formula 1 are described, in which R1 is substituted C1-C6-alkyl and C3-C9-cycloalkyl, R2, R3, R4 and R5 are hydrogen, halogen, nitro, C1-C4-alkyl, C1-C9-alkyloxy, substituted C6-C10-aryl-C1-C4-alkyloxy, C6-C10-aryloxy, C6-C10-aryl, C3-C8-cycloalkyl or O—C3—C8-cycloalkyl, or 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl or NR6-A-R7, with the proviso that R2, R3, R4 and R5 are not simultaneously hydrogen, and at least one of the radicals R2, R3, R4 or R5 is the radical 2-oxopyrrolidin-1-yl, 2,5-dimethylpyrrol-1-yl or NR6-A-R7, wherein R6=hydrogen, C1-C4-alkyl or substituted C6-C10-aryl-C1-C4-alkyl, A=a single bond, COn, SOn or CONH, n=1 or 2, R7=hydrogen, substituted C1-C18-alkyl, C2-C18-alkenyl, C6-C10-aryl-C1-C4-alkyl, C5-C8-cycloalkyl-C1-C4-alkyl, C5-C8-cycloalkyl, C6-C10-aryl-C2-C6-alkenyl, C6-C10-aryl, biphenylyl, biphenylyl-C1-C4-alkyl, indanyl, or the group Het-(CH2)r—, wherein r&eq

Abstract: The present invention relates to a compound named Percyquinnin which is obtainable by cultivation of the fungus Basidiomycetes Stereum complicatum (DSM 13303), and to its pharmaceutically acceptable salts. The present invention further relates to a process for the production of Percyquinnin, to the microorganism Basidiomycetes Stereum complicatum (DSM 13303), to the use of Percyquinnin and its pharmaceutically acceptable salts as pharmaceuticals, in particular to their use as inhibitor of lipase, and to pharmaceutical compositions comprising Percyquinnin or a pharmaceutically acceptable salt thereof.

Abstract: Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones of the formula 1 are described, 1

Abstract: The invention relates to inositolglycans having insulin-like action. Specific compounds are provided having the formula IA--Z--R (I)where A is the radical H--P(O)(OH)--, H--P(S)(OH)--, HO--P(S)(OH)--, HS--P(S)(OH)--, (C.sub.1 -C.sub.4)-alkyl-P(O)(OH)--, (C.sub.1 -C.sub.4)-alkyl-P(S)(OH)--, S(O).sub.2 (OR.sup.1)--, S(O)(OR.sup.1)--, NH.sub.2 --C(O)--, R.sup.1 R.sup.2 N--, R.sup.1 R.sup.2 N--C(O)--NH--, R.sup.1 O--SO.sub.2 --NH--, (C.sub.1 -C.sub.4)-alkyl-SO.sub.2 --, (C.sub.1 -C.sub.4)-alkyl-S(O)-- or R.sup.1 --S--, Z is 2 to 6 substituted or unsubstituted sugar radicals and R is substituted or unsubstituted inositol. The inventive compounds are suitable for the treatment of diabetes mellitus or noninsulin-dependent diabetes.

Abstract: A process for the safe supply of molecular oxygen or gas containing molecular oxygen to an oxidation of hydrocarbons in the liquid phase, wherein, immediately before the point of entry into the liquid hydrocarbon, the oxygen, or gas containing oxygen, to be supplied is at least 20.degree. C. colder than the hydrocarbon, and wherein, as soon as the oxygen, or gas containing oxygen, which is to be supplied exceeds the predetermined temperature at the supply orifice, the supply ceases.